Ranitidine, a widely used medication for reducing stomach acid, has found itself under scrutiny due to safety concerns regarding the presence of N-nitrosodimethylamine (NDMA), a potentially cancer-causing impurity. While several countries have banned or restricted the drug, India’s health authorities are taking a measured approach, focusing on ensuring safety without disrupting its availability.

For decades, Ranitidine has been a trusted treatment for conditions like acid reflux and peptic ulcers. Known by brand names such as Aciloc, Rantac, and Zinetac in India, it has been a staple in medicine cabinets. However, concerns escalated when an independent investigation revealed significant amounts of NDMA in Ranitidine formulations. NDMA is classified as a probable human carcinogen, which means prolonged exposure could potentially lead to cancer.

The alarm over NDMA began with a U.S.-based pharmacy, Valisure, which flagged that certain versions of Ranitidine, including Zantac, contained excessive NDMA levels. This triggered a global reaction, leading to bans and recalls in multiple countries, including the United States. Pharmaceutical giant GSK, the manufacturer of Zantac, eventually agreed to settle lawsuits amounting to $2.2 billion.

Unlike the U.S., India has opted for a cautious yet proactive strategy. The Central Drugs Standard Control Organisation (CDSCO), India’s drug regulatory authority, has taken several steps to ensure that the medication remains safe for consumption. Minister of State for Health Anupriya Patel recently assured the public that there are no plans to ban Ranitidine. However, rigorous measures have been implemented to monitor and control NDMA levels in the drug.

The CDSCO has instructed manufacturers to verify their formulations and comply with updated safety standards. Zonal offices across the country have been directed to collect samples of Ranitidine from various sources for NDMA analysis. Furthermore, the Indian Pharmacopoeia Commission has included guidelines for detecting nitrosamine impurities in the 9th edition of the Indian Pharmacopoeia, setting clear intake limits for such substances.

Why the Drug Remains Available
Ranitidine’s widespread use in India is a significant factor in the decision not to impose a blanket ban. The medication is not just affordable but also effective for managing common gastrointestinal issues. Eliminating it entirely from the market could disrupt treatment for millions of patients, especially those in rural areas where alternatives may be less accessible or affordable.

Additionally, while international regulatory agencies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have highlighted NDMA risks, they have not entirely dismissed the possibility of safe formulations. This provides Indian authorities with a framework to refine and regulate the drug rather than withdraw it altogether.

The controversy surrounding Ranitidine is far from limited to India. GSK’s settlement of $2.2 billion for Zantac-related lawsuits underscores the global impact of the issue. The legal cases were fuelled by allegations that NDMA contamination in Zantac was linked to cancer diagnoses. By mid-2025, approximately 80,000 cases are expected to be resolved under the settlement agreement.

This legal backdrop serves as a cautionary tale for pharmaceutical companies and regulators worldwide. It highlights the importance of stringent quality control measures and transparent communication with the public.

One of the challenges in addressing the Ranitidine issue is the complexity of NDMA formation. Studies suggest that NDMA can form when Ranitidine interacts with stomach acid, particularly under specific conditions. This makes it difficult to predict and control NDMA levels, necessitating advanced testing methods and stricter manufacturing protocols.

The Indian Pharmacopoeia’s inclusion of nitrosamine impurity guidelines is a step forward. By establishing acceptable intake limits and analytical methods, it equips manufacturers with the tools to produce safer formulations. However, these measures must be complemented by robust enforcement and regular monitoring.

Patient Safety vs. Market Stability
The balancing act between ensuring patient safety and maintaining drug availability is at the heart of India’s response to the Ranitidine controversy. For many, the drug is indispensable, offering relief from painful symptoms at an affordable cost. Yet, the risks associated with NDMA cannot be ignored.

To address these concerns, a multi-pronged approach is necessary. This includes:

1.    Public Awareness: Educating patients about the potential risks and encouraging them to consult healthcare professionals for advice.

2.    Alternative Treatments: Promoting the use of safer alternatives for acid reflux and related conditions, especially for high-risk patients.

3.    Regulatory Oversight: Strengthening the CDSCO’s capacity to monitor and regulate pharmaceuticals effectively.

The Ranitidine case highlights broader issues in drug safety and regulation. It highlights the need for a proactive approach to identifying and addressing risks before they escalate into global crises. For pharmaceutical companies, it serves as a reminder of their responsibility to prioritize patient safety over profits.

For regulators, the incident offers valuable lessons on the importance of international collaboration. NDMA contamination is not confined to a single country or manufacturer; it is a global issue requiring a unified response. Sharing data, expertise, and resources can help address such challenges more effectively.

The controversy surrounding Ranitidine is a wake-up call for the healthcare industry. While the drug continues to be available in India, the emphasis on safety measures reflects a commitment to protecting public health. By using scientific advancements and enforcing stringent regulations, India can ensure that essential medications like Ranitidine remain both safe and accessible.

As patients, healthcare providers, and policymakers navigate this complex issue, one thing is clear: the path forward lies in striking a delicate balance between caution and progress. Through collective efforts, it is possible to turn the challenges of today into opportunities for a safer, healthier tomorrow